Nonetheless, over‐expression of EGFR exhibited in 10–44% of iCCA patients.[7, 8] Additionally, a subtype of iCCA patients was previously reported with active EGFR signaling.[9] Clinical trials have been conducted to evaluate the efficacy of EGFR TKIs and neutralizing antibodies in iCCA patients, although the focus has primarily been on combining these treatments with chemotherapy drugs rather than using EGFR TKIs alone. Here, EGFR is linked to infantile convulsions and choreoathetosis.